We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Gestational Diabetes May Predict Autoimmune Diabetes Risk

By LabMedica International staff writers
Posted on 15 Jun 2021
Print article
Image: Women diagnosed with gestational diabetes are more likely to be autoantibody positive and develop type 1 diabetes in the decade after delivery compared with pregnant women without gestational diabetes (Photo courtesy of Kernodle Clinic)
Image: Women diagnosed with gestational diabetes are more likely to be autoantibody positive and develop type 1 diabetes in the decade after delivery compared with pregnant women without gestational diabetes (Photo courtesy of Kernodle Clinic)
Gestational diabetes is high blood sugar (glucose) that develops during pregnancy and usually disappears after giving birth. It can happen at any stage of pregnancy, but is more common in the second or third trimester.

Autoimmune diabetes, commonly referred to as type 1 diabetes mellitus (an older synonym is insulin-dependent diabetes mellitus), is a chronic immune-mediated disease characterized by insulin deficiency due to pancreatic islet beta-cell destruction with increasing blood glucose levels.

Medical Scientists at the Helsinki University Hospital (Helsinki, Finland) in a prospective cohort study, analyzed data from 391 women with gestational diabetes and 391 age-, parity- and delivery date-matched controls who delivered from 1984 through 1994 and underwent autoantibody testing during the first trimester of pregnancy. The team assessed levels of four autoantibodies associated with type 1 diabetes: Islet cell autoantibodies (ICA), glutamic acid decarboxylase autoantibodies (GADA), insulin autoantibodies (IAA) and insulinoma-associated antigen-2 autoantibodies (IA-2A). Women completed a follow-up questionnaire assessing later type 1 or type 2 diabetes diagnosis in 2012-2013. The mean follow-up time was 23 years.

The scientists observed single autoantibody positivity in 41(12%) of the gestational diabetes cohort and in eight (2.3%) of the control cohort. In the gestational diabetes cohort, nine (2.6%) tested positive for two autoantibodies and eight (2.3%) tested positive for three autoantibodies, whereas only one woman in the control cohort had two autoantibodies detected. Islet cell autoantibodies (ICA) positivity was found in 12.5% of cases, followed by GADA (6%), IA-2A (4.9%) and IAA (1.2%). In the control cohort, GADA positivity was found in 1.4% of cases, followed by IA-2A (0.8%), IAA (0.6%) and ICA (0.3%). All women with three positive autoantibodies developed type 1 diabetes within seven years from pregnancy with gestational diabetes. Development of type 2 diabetes and gestational diabetes occurred independent of autoantibody positivity.

Kaisu Luiro-Helve, MD, PhD, consultant in obstetrics and gynecology and reproductive endocrinology and senior author of the study, said, “If you are not the typical gestational diabetes candidate, but you have it, that may warrant more screening. Type 1 diabetes is not just a disease of the young. Type 1 usually occurs within 10 years of gestational diabetes, and that is the time when we need to stay alert and perhaps conduct another oral glucose tolerance test. Do not forget about these women after delivery.” The study was presented at the European Congress of Endocrinology virtual meeting held May 22-26, 2021.

Related Links:
Helsinki University Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.